Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05787587 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 23 → 27 locationsv22
  2. Trial status changed: Recruiting → Active, Not Recruiting Trial sites reduced: 27 → 23 locationsv21 Show 1 more changeShow less
    • Trial sites reduced: 27 → 23 locations
  3. Start date: Apr 5, 2023 to Apr 18, 2023v20
  4. Site details revised at 6 of 27 sitesv19
  5. Re-verified, no change to tracked fieldsv18
Show 16 earlier versionsHide 16 earlier versions
  1. Site details revised at 5 of 27 sitesv17
  2. Study sites: 25 to 27v16
  3. Study sites: 23 to 25v15
  4. Enrollment target: 68 to 216 Primary completion date: Jun 2025 to Oct 2026 · Primary endpoints: 4 to 3 · Study sites: 24 to 23 · 7 morev14 Show 10 more changesShow less
    • Primary completion date: Jun 2025 to Oct 2026
    • Primary endpoints: 4 to 3
    • Study sites: 24 to 23
    • Completion date: Sep 2025 to May 2027
    • Interventions: IDE-161 (Drug) to IDE-161 (Drug), Pembrolizumab (Drug)
    • Eligibility criteria expanded, about 125 words
    • Secondary endpoints: 5 to 7
    • Study description expanded, about 11 words
    • Study arms: 2 to 4
    • Collaborators expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  5. Site details revised at 3 of 24 sitesv13
  6. Site details revised at 5 of 24 sitesv12
  7. Site contacts updated at 9 of 24 sitesv11
  8. Study sites revised (24)v10 See this version in full on ClinicalTrials.gov ↗
  9. Study sites: 15 to 24v9
  10. Site contacts updated at 6 of 15 sitesv8
  11. Study sites: 12 to 15v7
  12. Study sites: 9 to 12v6
  13. Study sites: 5 to 9v5
  14. Study sites: 1 to 5v4
  15. Re-verified, no change to tracked fieldsv3
  16. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Mar 2023 to Apr 5, 2023 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Mar 2023 to Apr 5, 2023
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
IDEAYA Biosciences
11 trials monitored
See all monitored trials
Breast Cancer
5,213 trials monitored
See 271 trials at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
2,932 trials monitored
See 157 trials at risk
and 6 more diseases
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Trial Details
NCT Number NCT05787587
Lead Sponsor IDEAYA Biosciences
Collaborators: Merck Sharp & Dohme LLC
Conditions Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC) +1 more
Enrollment 216 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov